Aquestive Therapeutics
Aquestive Therapeutics' revenue fell 22.6% to $44 million in fiscal 2025. Its operating margin was −159.5%, down from −53.5% a year earlier. Free cash flow was −$53 million. The diluted share count rose 23.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Aquestive Therapeutics does
Aquestive Therapeutics is a drug company that develops medicines meant to be given in ways other than injections and other inconvenient routes. Its main technology is PharmFilm, a thin film about the size of a postage stamp that dissolves in the mouth and delivers a drug into the bloodstream. It says it has been the main maker of oral films for prescription drugs.
It makes money from four licensed products that its partners sell in the U.S. and elsewhere. Aquestive is the exclusive manufacturer of these products and makes them at its plant in Portage, Indiana. It also works with other drug companies to bring new drugs to market using its technology.
Its main candidate in development is Anaphylm, an epinephrine film for severe allergic reactions including anaphylaxis, which needs no device. The FDA sent the company a complete response letter for it, meaning the agency did not approve it as submitted. Aquestive is also developing a platform of epinephrine prodrugs, which are compounds the body converts into epinephrine. Its headquarters and main laboratories are in Warren, New Jersey.
Its biggest risks, as it describes them
- Anaphylm may not win approval, after the FDA's complete response letter.
- Clinical trials of its candidates may be delayed, halted or ended.
- It has limited experience selling its own products and may lack the people and resources to launch them.
- Its licensed and proprietary products may not gain acceptance from patients, doctors and pharmacists.
- Competition from other drug companies, and legal actions from competitors or collaborators.
Income statement
Aquestive Therapeutics lost money in fiscal 2025: a net loss of $84 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 28 | 27 | 24 | 72 | 121 |
| Debt incl. finance leases | — | 33 | 45 | 45 | 45 |
| Net debt (negative means net cash) | — | 6 | 21 | −26 | −76 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −3.5x | −6.4x | −2.4x | −2.8x | −6.4x |
| Current ratio | 2.1x | 1.0x | 2.2x | 4.7x | 3.1x |
| Quick ratio | 2.0x | 0.9x | 1.9x | 4.4x | 3.0x |
Cash flow
Projections
Project Aquestive Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Aquestive Therapeutics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 5 of 9 | 2 of 9 |
| Rule of 40 | −8.5% | −48.6% | −141.6% |
| Altman Z'' | −17.98 | −9.62 | −8.08 |
| Accruals ratio | −2.6% | −10.6% | −23.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Pass |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 4 of 9 | 5 of 9 | 2 of 9 |
Compare
Put Aquestive Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Aquestive Therapeutics | FY25 | −22.6% | −159.5% | −119.0% | — | — | 2 | |
| Ocular Therapeutix | FY25 | −18.5% | −519.8% | −417.5% | — | — | 4 | Compare |
| Agios Pharmaceuticals | FY25 | 48.0% | −873.9% | −698.3% | — | — | — | Compare |
| Nektar Therapeutics | FY25 | −43.9% | −253.7% | −377.8% | — | — | 2 | Compare |
| Tango Therapeutics | FY25 | 48.3% | −178.4% | −224.3% | — | — | — | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 67 | 67 | 53 | 46 | 51 | 48 | 51 | 58 | 44 |
| Revenue growth | — | 0.8% | −22.0% | −12.8% | 10.9% | −6.2% | 6.1% | 13.8% | −22.6% |
| Gross profit | — | — | 32 | 33 | — | 28 | 30 | 40 | 26 |
| Research and development | 22 | 23 | 21 | 20 | 17 | 18 | 13 | 20 | 17 |
| Operating income | −0 | −49 | −53 | −43 | −35 | −42 | −15 | −31 | −71 |
| Net income | −9 | −61 | −66 | −56 | −70 | −54 | −8 | −44 | −84 |
| Diluted EPS (US$) | — | −2.96 | −2.61 | −1.66 | −1.85 | −1.12 | −0.13 | −0.51 | −0.78 |
| Diluted shares (millions) | — | 21 | 25 | 34 | 38 | 49 | 61 | 87 | 107 |
| Cash flow | |||||||||
| Cash from operations | 6 | −13 | −60 | −46 | −33 | −10 | −6 | −36 | −52 |
| Capital expenditure | 2 | 2 | 1 | 0 | 1 | 1 | 1 | 0 | 1 |
| Free cash flow | 4 | −15 | −61 | −46 | −34 | −11 | −7 | −36 | −53 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 30 | 7 | 7 | 7 | 4 | 3 | 7 | 8 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 17 | 61 | 49 | 32 | 28 | 27 | 24 | 72 | 121 |
| Debt incl. finance leases | — | — | 70 | 52 | — | 33 | 45 | 45 | 45 |
| Total assets | 43 | 87 | 78 | 63 | 62 | 57 | 57 | 101 | 160 |
| Total liabilities | 70 | 77 | 85 | 111 | 144 | 176 | 164 | 162 | 194 |
| Shareholders' equity | −26 | 10 | −6 | −48 | −82 | −119 | −106 | −60 | −34 |
| Margins and ratios | |||||||||
| Gross margin | — | — | 61.3% | 71.7% | — | 59.3% | 58.8% | 69.0% | 58.4% |
| Operating margin | −0.2% | −72.6% | −100.1% | −93.5% | −68.2% | −88.2% | −29.9% | −53.5% | −159.5% |
| Net margin | −13.4% | −91.0% | −125.9% | −121.7% | −138.8% | −114.1% | −15.6% | −76.7% | −188.1% |
| Free cash flow margin | 5.6% | −22.0% | −115.7% | −100.3% | −66.7% | −22.7% | −14.6% | −62.4% | −119.0% |
| Rule of 40 (growth + FCF margin) | — | −21.2% | −137.7% | −113.1% | −55.8% | −28.9% | −8.5% | −48.6% | −141.6% |
| Return on capital | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | — | — | — | — | — | — | — |
| Return on assets | — | −94.5% | −80.1% | −78.9% | −113.0% | −91.4% | −13.8% | −55.6% | −64.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |